Business
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3
About this update from Eyepoint, Inc.
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments. “Following a year of exceptional execution across our pivotal DURAVYU programs, EyePoint enters 2026 from a position of strength as we prepare to deliver on key Phase 3 milestones and showcase the potential of DURAVYU’s best-in-class safety and efficacy profile,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “We expect to report Phase 3 topline data in wet AMD beginning in mid-2026, and we are confident that our de-risked approach and non-inferiority pathway position us to potentially obtain a broad and favorable label. DURAVYU is the only TKI in development for the treatment of DME and, with the recent first patient dosing in our COMO and CAPRI Phase 3 trials, we now have active pivotal programs in the largest multi-billion-dollar retina markets. Our clinical timeline positions DURAVYU to be first to market among current investigational sustained delivery programs in these large and growing indications.” Dr. Duker continued, “Looking ahead, we remain focused on regulatory and commercial readiness to support an efficient NDA filing and deliver DURAVYU to wet AMD patients as quickly as possible. With our strong balance sheet, DURAVYU’s clinical and mechanistic differentiation, and our rapidly approaching Phase 3 readouts, we are optimally positioned to continue our leadership in sustained drug delivery and address the needs of patients living with serious retinal diseases.” R&D Highlights and Updates DURAVYU in Wet Age-Related Macular Degeneration (Wet AMD) LUGANO topline data is anticipated in mid-2026, with LUCIA topline data expected shortly after. LUGANO and LUCIA are identica...